Alba, Maria

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 233

Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes

Peters, A. L., Henry, R. R., Thakkar, P., Tong, C., & Alba, M. (2016) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 106

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study

Alba, M., Yee, J., Frustaci, M. E., Samtani, M. N., & Fleck, P. (2021) · Clinical Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 100

The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes

Rodbard, H. W., Peters, A. L., Slee, A., Cao, A., Traina, S. B., & Alba, M. (2017) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 94

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study

Di Prospero, N. A., Yee, J., Frustaci, M. E., Samtani, M. N., Alba, M., & Fleck, P. (2021) · Clinical Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 60